{"id":29880,"date":"2025-04-11T00:54:48","date_gmt":"2025-04-10T22:54:48","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/04\/11\/a-frameshift-generated-cancer-neoepitope-that-controls-tumor-burden-in-prophylaxis-as-well-as-therapy\/"},"modified":"2025-04-11T00:54:48","modified_gmt":"2025-04-10T22:54:48","slug":"a-frameshift-generated-cancer-neoepitope-that-controls-tumor-burden-in-prophylaxis-as-well-as-therapy","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/04\/11\/a-frameshift-generated-cancer-neoepitope-that-controls-tumor-burden-in-prophylaxis-as-well-as-therapy\/","title":{"rendered":"A frameshift-generated cancer neoepitope that controls tumor burden in prophylaxis as well as therapy"},"content":{"rendered":"<div>\n<p><b>J Immunol<\/b>. 2025 Apr 10:vkaf016. doi: 10.1093\/jimmun\/vkaf016. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Insertion or deletion of one or two base pairs within a coding region causes a frameshift, which has the potential to generate neoepitopes (InDel-generated neoepitopes) that lack a self-counterpart and are entirely novel. Despite the obvious appeal of InDel-generated neoepitopes, and the demonstration of such candidate neoepitopes that can elicit a CD8 T-cell response, no InDel-generated neoepitopes that actually control tumors in vivo have been reported thus far. Here, in a mouse colon carcinoma line, we identify 11 InDels, only one of which generates a neoepitope that elicits tumor control in vivo in models of prophylaxis as well as therapy. Although this neoepitope has no self-counterpart, it has a low affinity (IC50 33,937.60 nM) for its MHC I allele. Despite its low affinity for MHC I, this neoepitope elicits antitumor activity in vivo through CD8 T cells. Furthermore, CD8 T cells elicited by this InDel-generated neoepitope, like the neoepitopes created by point mutations, show notably less exhaustion than classical immunogenic epitopes. Ironically, this InDel-generated neoepitope follows the same rules as noted for most of the tumor control-mediating neoepitopes generated by point mutations that have a poor affinity for MHC I alleles.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40209093\/?utm_source=WordPress&amp;utm_medium=rss&amp;utm_content=2985117R&amp;ff=20250410185447&amp;v=2.18.0.post9+e462414\">40209093<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1093\/jimmun\/vkaf016\">10.1093\/jimmun\/vkaf016<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Immunol. 2025 Apr 10:vkaf016. doi: 10.1093\/jimmun\/vkaf016. Online ahead of print. ABSTRACT Insertion or deletion of one or two base pairs within a coding region causes a frameshift, which has the potential to generate neoepitopes (InDel-generated neoepitopes) that lack a self-counterpart and are entirely novel. Despite the obvious appeal of InDel-generated neoepitopes, and the demonstration &#8230; <a title=\"A frameshift-generated cancer neoepitope that controls tumor burden in prophylaxis as well as therapy\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/04\/11\/a-frameshift-generated-cancer-neoepitope-that-controls-tumor-burden-in-prophylaxis-as-well-as-therapy\/\" aria-label=\"Read more about A frameshift-generated cancer neoepitope that controls tumor burden in prophylaxis as well as therapy\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,71],"tags":[],"class_list":["post-29880","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-the-journal-of-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/29880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=29880"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/29880\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=29880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=29880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=29880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}